Aclaris Therapeutics, Inc. (ACRS) Income Statement Analysis

See more : Jiangsu Jingyuan Environmental Protection Co., Ltd. (688096.SS) Income Statement Analysis – Financial Results

Complete financial analysis of Aclaris Therapeutics, Inc. (ACRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aclaris Therapeutics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

PT Mitra Komunikasi Nusantara Tbk (MKNT.JK) Income Statement Analysis – Financial Results
ESGEN Acquisition Corporation (ESAC) Income Statement Analysis – Financial Results
PTC India Financial Services Limited (PFS.NS) Income Statement Analysis – Financial Results
Koge Micro Tech Co., Ltd. (4568.TWO) Income Statement Analysis – Financial Results
Partner Communications Company Ltd. (PTNR) Income Statement Analysis – Financial Results

Aclaris Therapeutics, Inc. (ACRS)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.aclaristx.com

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	31.25M	29.75M	6.76M	6.48M	4.23M	10.09M	1.68M	0.00	0.00	0.00	0.00
Cost of Revenue	18.08M	11.96M	4.71M	5.13M	4.06M	6.85M	1.21M	120.00K	90.00K	0.00	0.00
Gross Profit	13.17M	17.79M	2.05M	1.35M	172.00K	3.24M	476.00K	-120.00K	-90.00K	0.00	0.00
Gross Profit Ratio	42.14%	59.80%	30.29%	20.81%	4.07%	32.12%	28.28%	0.00%	0.00%	0.00%	0.00%
Research & Development	98.38M	77.81M	43.81M	31.73M	64.90M	63.01M	39.79M	33.48M	15.34M	6.51M	3.49M
General & Administrative	31.10M	25.13M	23.62M	20.53M	27.16M	27.65M	33.11M	15.09M	5.33M	2.03M	1.77M
Selling & Marketing	0.00	0.00	0.00	283.00K	671.00K	48.00M	85.00K	3.30M	0.00	0.00	0.00
SG&A	31.10M	25.13M	23.62M	20.53M	27.83M	75.65M	33.11M	15.09M	5.33M	2.03M	1.77M
Other Expenses	0.00	2.95M	-1.14M	-424.00K	-2.48M	2.68M	2.07M	488.00K	0.00	0.00	0.00
Operating Expenses	130.80M	102.95M	67.43M	52.26M	92.73M	138.66M	72.90M	48.57M	20.67M	8.53M	5.26M
Cost & Expenses	128.61M	114.91M	72.15M	57.39M	96.78M	145.51M	74.11M	48.57M	20.67M	8.53M	5.26M
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	104.00K	16.00K	21.00K
Interest Expense	0.00	4.70M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	863.00K	797.00K	923.00K	1.32M	1.59M	1.32M	402.00K	120.00K	90.00K	12.00K	11.00K
EBITDA	-117.57M	-84.36M	-65.06M	-48.20M	-90.84M	-80.78M	-53.45M	-48.57M	-20.67M	-8.52M	-5.25M
EBITDA Ratio	-376.22%	-267.74%	-607.08%	-785.44%	-1,751.83%	-1,341.93%	-4,303.21%	0.00%	0.00%	0.00%	0.00%
Operating Income	-97.36M	-85.15M	-65.38M	-50.91M	-111.06M	-135.41M	-72.42M	-48.57M	-20.67M	-8.53M	-5.26M
Operating Income Ratio	-311.55%	-286.21%	-967.08%	-785.44%	-2,627.35%	-1,341.93%	-4,303.21%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	8.51M	2.95M	-1.14M	-424.00K	-2.48M	2.68M	-15.99M	488.00K	104.00K	16.00K	21.00K
Income Before Tax	-88.85M	-86.91M	-90.87M	-51.34M	-113.54M	-132.74M	-70.35M	-48.08M	-20.56M	-8.52M	-5.24M
Income Before Tax Ratio	-284.32%	-292.11%	-1,343.96%	-791.98%	-2,686.11%	-1,315.41%	-4,180.21%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-367.00K	1.75M	23.42M	-182.00K	29.31M	2.68M	-1.83M	-120.00K	-90.00K	0.00	0.00
Net Income	-88.48M	-88.66M	-114.28M	-51.15M	-142.85M	-132.74M	-68.52M	-48.08M	-20.56M	-8.52M	-5.24M
Net Income Ratio	-283.15%	-298.00%	-1,690.30%	-789.17%	-3,379.47%	-1,315.41%	-4,071.48%	0.00%	0.00%	0.00%	0.00%
EPS	-1.27	-1.36	-2.01	-1.20	-3.46	-4.03	-2.44	-2.25	-3.37	-0.80	-0.49
EPS Diluted	-1.27	-1.36	-2.01	-1.20	-3.46	-4.03	-2.44	-2.25	-3.37	-0.80	-0.49
Weighted Avg Shares Out	69.81M	65.21M	56.73M	42.54M	41.32M	32.91M	28.10M	21.42M	6.11M	10.66M	10.66M
Weighted Avg Shares Out (Dil)	69.81M	65.21M	56.73M	42.54M	41.32M	32.91M	28.10M	21.42M	6.11M	10.66M	10.66M

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 7, 2024globenewswire.com

- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel...

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

April 23, 2024prnewswire.com

CAMBRIDGE, Mass. , April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D.

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

April 5, 2024zacks.com

Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

March 20, 2024zacks.com

Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.

Aclaris (ACRS) Upgraded to Buy: Here's Why

March 4, 2024zacks.com

Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

March 4, 2024zacks.com

Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

February 27, 2024zacks.com

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.41 per share a year ago.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

February 27, 2024globenewswire.com

WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023...

Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know

February 15, 2024zacks.com

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.